Results 51 to 60 of about 2,911,119 (244)
BMC Pulmonary Medicine, 2021 Background The identification of NTRK fusions in tumours has become critically important due to the actionable events predictive of response to TRK inhibitor.
Lei Zhang +4 more
doaj +1 more source
Lapatinib potentiates cytotoxicity of YM155 in neuroblastoma via inhibition of the ABCB1 efflux transporter [PDF]
, 1967 Adverse side effects of cancer agents are of great concern in the context of childhood tumors where they can reduce the quality of life in young patients and cause life-long adverse effects.
Brunak, Søren +8 more
core +3 more sources
Clinical Cancer Research, 2020 Purpose: Taletrectinib (DS-6051b/AB-106) is an oral, tyrosine kinase inhibitor of ROS1 and NTRK with potent preclinical activity against ROS1 G2032R solvent-front mutation among others. We report the first-in-human U.S.
K. Papadopoulos +23 more
semanticscholar +1 more source
EJNMMI Research, 2022 Background Tropomyosin receptor kinases (TrkA, TrkB, TrkC) are a family of tyrosine kinases primarily expressed in neuronal cells of the brain. Identification of oncogenic alterations in Trk expression as a driver in multiple tumor types has increased ...
Melinda Wuest +7 more
doaj +1 more source
Potential novel therapy targets in neuroendocrine carcinomas of the breast [PDF]
, 2018 Neuroendocrine carcinoma (NEC) of the breast is a rare, special type of breast cancer, reportedly constituting 2% to 5% of all breast cancers. Although breast NEC does not have a specific targeted therapy, several new targeted therapies based on specific
Contreras, Elma +7 more
core +2 more sources
Frontiers in Oncology, 2023 The family of the neurotrophic tyrosine kinase receptor (NTRK) gene encodes for members of the tropomyosin receptor kinase (TRK) family. Rearrangements involving NTRK1/2/3 are rare oncogenic factors reported with variable frequencies in an extensive ...
Selene Cipri +7 more
doaj +1 more source
Nerve growth factor, brain-derived neurotrophic factor, and the chronobiology of mood: a new insight into the "neurotrophic hypothesis" [PDF]
, 2015 The light information pathways and their relationship with the body rhythms have generated a new insight into the neurobiology and the neurobehavioral sciences, as well as into the clinical approaches to human diseases associated with disruption of ...
IANNITELLI, ANGELA +2 more
core +2 more sources
Dramatic Responses Seen with TRK Inhibitor [PDF]
Cancer Discovery, 2017 Abstract Presenting data on 50 of 55 patients with advanced TRK fusion–positive tumors, researchers reported that 76% of patients responded to the selective pan-TRK inhibitor larotrectinib, and 12% of patients experienced complete responses; 93% of responders remain on therapy.
openaire +2 more sources
Tracking Down Response and Resistance to TRK Inhibitors [PDF]
Cancer Discovery, 2016 Abstract Summary: Two recent studies validate the LMNA–NTRK1 fusion as an oncogenic driver and therapeutic target of TRK inhibitors. The LMNA–NTRK1 fusion occurs at low frequency across multiple tumor types. The studies highlight the increasing need to develop molecular biomarker–based clinical trials across cancer subtypes.Cancer Discov;
Okimoto, Ross A, Bivona, Trever G
openaire +4 more sources
Inducers of epithelial mesenchymal transition and cancer stem cells in malignant pleural effusions [PDF]
, 2016 The Epithelial to Mesenchymal Transition (EMT) plays a role not only in tumor metastasis but also in tumor recurrence. This process is believed to be tightly linked to the presence of Cancer Stem Cells (CSCs) however, it is still not clear which ...
Cherubini, Emanuela +5 more
core +1 more source